Progesterone Articles & Analysis: Older
12 news found
Antiprogestins act as Progesterone Receptor (PgR) antagonists. Novel and promising class of drugs to overcome endocrine resistance associated with ESR1 mutations. ...
(“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended release (ONA-XR), the company’s novel, first-in-class, potent, orally administered progesterone receptor (PR) antagonist, ...
The primary objective of the Phase 2 portion will be to evaluate the efficacy of the combination at the RP2D, as measured by progression-free survival at 24 weeks. The estrogen/progesterone receptor status of participants will be recorded as part of an exploratory objective. ...
“LightDeck was central in developing Heska’s leading immunodiagnostic platform, Element i+®, including its current menu of Total T4, cTSH, Cortisol, and Progesterone. Having proven our capability, we now take this next important step as we aim to drive production of Element i+® analyzers and cartridges at scale and to accelerate key test menu expansion, such ...
“We look forward to the presentations from investigators on lead product candidate onapristone extended release (ONA-XR), a potent, specific progesterone receptor (PR) antagonist being evaluated for PR+ breast, ovarian and endometrial cancer, and our preclinical anti-claudin 6 (CLDN6) bispecific monoclonal antibody (BsMAb) for gynecologic cancer ...
PGR is an estrogen-responsive gene and progesterone receptor (PR) expression, evaluated by immunohistochemistry (IHC), is used as a clinical biomarker of estrogen signaling and estrogen receptor (ER) functionality.1 Despite the well-studied role of PGR as mitogen and independent ER activator, anti-progestins for the treatment of BC have been poorly tested. ...
Extended release Onapristone (Onapristone ER) is a progesterone receptor (PR) antagonist that inhibits hormone-mediated PR activation and stabilizes PR association with compressors, resulting in an antineoplastic effect when applied alone or in combination with antiestrogen therapy to breast cancer cells in vitro (1). ...
Introduction Anliprogestins have demonstrated promising activity against breast and gynecological cancers, but liver-related safety concerns limited the advancement of this therapeutic class. Onapristone is a full progesterone receptor antagonist originally developed as an oral contraceptive and later evaluated in phase II studies for metastatic breast cancer. ...
” There are four distinct main molecular subtypes of breast cancer, which are defined based on the presence of hormone receptors (estrogen [ER] and progesterone [PR]) with or without human epidermal growth factor receptor 2 (HER2) protein overexpression or extra copies of the HER2 gene, and elevation of the ki67 proliferation marker. ...
In addition, we will review in detail the construct of the SPRi based NanoAptasensor, which allows you to analyze in a label-free and real time manner ultra-sensitively and selectively hormones like progesterone. Register Now! Key Learning Objectives Understand the key differences between aptamers and antibodies Learn how the X-Aptamer Selection Kit works to identify ...
In addition, we will review in detail the construct of the SPRi based NanoAptasensor, which allows you to analyze in a label-free and real time manner ultra-sensitively and selectively hormones like progesterone. Register Now! Key Learning Objectives Understand the key differences between aptamers and antibodies Learn how the X-Aptamer Selection Kit works to identify ...
“The peak of autoimmunity in females compared to males during the 40-49 age bracket is suggestive of the effects that the hormones estrogen and progesterone might be playing on the immune system,” said Linda Birnbaum, Ph.D., director of NIEHS and an author on the paper. ...